PEPTIDE VACCINE FOR INFLUENZA VIRUS

• US 20100074920A1
• Filed: 10/26/2007
• Published: 03/25/2010
• Est. Priority Date: 10/26/2006
• Status: Abandoned Application

• Current Assignee: Glykos Finland Oy
• Original Assignee: Glykos Finland Oy
• Inventors: Helin, Jari, Natunen, Jari, Aitio, Olli, Niemela, Ritva, Hiltunen, Jukka
• Application Number:
  US12/447,018
• Publication Number:
  US 20100074920A1
• Time in Patent Office: Days
• US Class Current: 424/209.100
• CPC Class Codes: A61K 2039/64 characterised by the architecture of the carrier-antigen complex, e.g. repetition of carrier-antigen units
• CPC Class Codes: A61K 38/00 Medicinal preparations containing peptides peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00
• CPC Class Codes: A61K 39/00 Medicinal preparations containing antigens or antibodies materials for immunoassay G01N33/53
• CPC Class Codes: A61K 39/12 Viral antigens
• CPC Class Codes: A61K 39/145 Orthomyxoviridae, e.g. influenza virus
• CPC Class Codes: A61P 31/12 Antivirals
• CPC Class Codes: A61P 31/16 for influenza or rhinoviruses
• CPC Class Codes: A61P 37/04 Immunostimulants
• CPC Class Codes: C07K 14/005 from viruses
• CPC Class Codes: C07K 5/0815 with the first amino acid being basic
• CPC Class Codes: C07K 5/0821 with the first amino acid being heterocyclic, e.g. His, Pro, Trp
• CPC Class Codes: C12N 2760/16122 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
• CPC Class Codes: C12N 2760/16134 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
• CPC Class Codes: G01N 2333/11 Orthomyxoviridae, e.g. influenza virus
• CPC Class Codes: G01N 33/56983 Viruses
• CPC Class Codes: Y10T 436/143333 Saccharide [e.g., DNA, etc.]

Abstract

The invention relates to the method for evaluating the potential of a chemical entity, such as an antibody, to bind to a peptide epitope derived from the divalent sialoside binding site of hemagglutinin protein of influenza virus. The invention also provides peptide epitopes 5 for use in the prevention and/or treatment of influenza or for the development of such treatment or vaccine against influenza.

Claims

1. A method for evaluating the potential of a chemical entity to bind to a peptide epitope derived from the divalent sialoside binding site of hemagglutinin protein of influenza virus comprising the steps of:

(i) contacting said chemical entity with said peptide under conditions that allow said chemical entity to bind said peptide; and

(ii) detecting the presence of a complex of said chemical entity and said peptide;

wherein said peptide epitope is peptide 1 corresponding to cysteine 97 region, and/or peptide 2 corresponding to cysteine 139 region and/or peptide 3 corresponding to the region of amino acids 220-226 as defined by the amino acid sequence of X31-hemaglutinin and

wherein

said peptide epitope comprises

a) a conformational peptide epitope, comprising at least one cysteine residue or cysteine analogous amino acid residue conjugated from the side chain and the peptide epitope comprises less than 100 amino acid residues, preferably less than 30 amino acid residues present in a natural influenza virus peptide or

b) the conformational peptide epitope is a short peptide epitope comprising 3 to 12 amino acid residues, preferably comprising less than 12 amino acid residues, more preferably less than 11 amino acid residue.

6. The method according to claim 1, wherein the conformational peptide epitope is

i) peptide 1 or peptide 2 conjugated from a cysteine or cysteine analogous residue side chain of the peptide epitope or

ii) peptide 3, which is in a cyclic form via a bridge formed by adding cysteine residues or cysteine analogous residues to the peptide sequence to form a loop comprising conformation similar to a peptide loop on the surface of hemagglutinin protein.

8. The method according to claim 1, wherein said peptide is selected from the group consisting of peptide 2 epitope cores including TSSACKR(R), TSSACIR(R), SS SACKR(R), (G)VTAACSH, (G)VTASCSH, (G)VSASCSH, GSNACKR, GSYACKR and GSSACKR or group consisting of peptide 3 epitope cores including RPRVRNI(P), RPKVRDQ, RPKVNGQ, RPRVRD(V/I/X)(P), RPRIRNI(P), RPWVRGL.

10. A conformational antigenic peptide or peptide composition comprising at least one peptide as described in claim 1, preferably comprising peptide 2 or peptide 3.

11. The antigenic peptide composition according to claim 10 comprising at least two peptides selected from the group peptide 1, peptide 2 and peptide 3, optionally at least two peptides from the group:

peptide 2 and peptide 3.

14. The method according to claim 1 wherein the method is used for selection of chemical entities, preferably antibodies, preferably from a library of the entities and the selection is performed in vivo, ex vivo or in vitro and optionally the detection is observing the result of the selection, optionally wherein the method involves specific conjugation of the peptide to matrix by a covalent bond or strong non-covalent interaction, and wherein covalent bond is formed from sulphur atom of a cysteine residue, optionally to maleimide or analogous structure or to a sulphur of cysteine in the matrix or the strong non-covalent interaction is binding of a ligand to a protein, optionally biotin binding to an avidin protein, optionally the peptide is biotinylated.

21. The method according to claim 1, wherein said peptide is selected from the group consisting of KVR-region peptides of hemagglutinin type 1, WVR-region peptides of hemagglutinin type 3, KVN-region peptides of hemagglutinin type 5, TSNSENGT(C)-region of hemagglutinin type 1, SKAFSN(C)-region peptides of hemagglutinin type 3, KXNPVNXL(C)-region of hemagglutinin type 5, TTKGVTAA(C)-region of hemagglutinin type 1, GGSNA-region peptides of hemagglutinin type 3, and DASSGVSSA(C)PY-region of hemagglutinin type 5.

26. The method according to the claim 1 for producing a peptide vaccine against influenza comprising steps of:

preparing said peptide conjugate

administering said peptide conjugate to an animal; and

monitoring the animal in order to detect immune response against the peptide

28. The peptide conjugate according to claim 10 comprising a carrier, other immunogenic peptides, or an adjuvant, wherein said peptide is optionally covalently linked to the surface of a carrier protein and wherein said peptide is preferably a peptide set forth in SEQ ID NO:

12.

33. The method according to the claim 1, further including evaluating the potential of a chemical entity to bind to:

a) a molecule or molecular complex comprising a large binding site defined by structure coordinates of influenza hemagglutinin amino acids Tyr98, Gly135, Trp153, His183, Leu194 and Gly225 of Region A; and

Ser95, Va1223, Arg224, Gly225 and Asn165 of Region B; and

Thr65, Ser71, Glu72, Ser95, Gly98, Pro99, Tyr100 and Arg269 of Region C according to FIG. 1;

or

b) a homologue of said molecule or molecular complex, wherein said homologue comprises a binding site that has a root mean square deviation from the backbone atoms of said amino acids of not more than 1.5 Å

comprising the steps of;

(i) employing computational means to perform a fitting operation between the chemical entity and the large binding site of the molecule or molecular complex; and

(ii) analyzing the results of said fitting operation to quantify the association between the chemical entity and the large binding site

and wherein said large binding site is optionally further defined by at least one of the structure coordinates of influenza hemagglutinin semi- or nonconserved amino acids Gly134, Asn137, Ala138, Thr155, Glu190 and Leu226 of Region A;

Phe94, Asn96, Asn137, Ala138, Lys140 and Arg207 of Region B;

Ser91, Ala 93, Tyr105 and Arg208 of Region C.

38. The method according to the claim 1, for identifying a modulator of binding between the large binding site of influenza hemagglutinin and its ligand divalent sialoside, comprising steps of:

(a) contacting the large binding site of influenza hemagglutinin and its ligand in the presence and in the absence of a putative modulator compound;

(b) detecting binding between the large binding site of influenza hemagglutinin and its ligand in the presence and absence of the putative modulator; and

(c) identifying a modulator compound in view of decreased or increased binding between the large binding site of influenza hemagglutinin and its ligand in the presence of the putative modulator, as compared to binding in the absence of the putative modulator, wherein the modulator binds to peptide epitope according to claim 1.

40. The method according to the claim 1, for selecting peptide epitopes for immunization and developing peptide vaccines against influenza comprising at least one di- to decapeptide epitope of the large binding site described in Table 1, wherein the method involves analysis according to the claim 1 for antibody as a chemical entity blocking the large binding site.

42. The method according to claim 1, using peptide 1, peptide 2 or peptide 3 selected from the group consisting of

K₁V₂R₃, W₁V₂R₃, K₁V₂N₃,

T₁P₂N₃P₄E₅N₆G₇T₈, S₁K₂A₃Y₄S₅N₆, K₁A₂N₃P₄A₅N₆D₇L₈,

V₁T₂K₃G₄V₅S₆A₇S₈, G₁T₂S₃S_AA₅, E₁A₂S₃S₄G₅V₆S₇S₈A₉, and said peptide corresponding to influenza virus A hemagglutinin.

43. The antigenic compound according to the claim 10 comprising a peptide selected from the group consisting of

K₁V₂R₃, W₁V₂R₃, K₁V₂N₃,

T₁P₂N₃P₄E₅N₆G₇T₈, S₁K₂A₃Y₄S₅N₆, K₁A₂N₃P₄A₅N₆D₇L₈,

V₁T₂K₃G₄V₅S₆A₇S₈, G₁T₂S₃S₄A₅, E₁A₂S₃S₄G₅V₆S₇S₈A₉, and said peptide corresponds to influenza virus A hemagglutinin.

57. The antigenic compound according to claim 1, wherein said antigenic compound comprises at least two peptides as defined in claim 1.

69. An isolated nucleotide encoding an antigenic compound as described in claim 1, the substance optionally being a primer.

70. The nucleotide according to the claim 69 for use in the method for detecting nucleic acid encoding antigenic compound according to claim 43 in a sample comprising:

amplifying DNA reverse transcribed from RNA obtained from the sample using one or more primers each comprising any one of the sequences as listed in Table 1 or sequences in FIGS. 17-19;

and detecting a product of amplification, wherein the presence of the product of amplification indicates the presence of an influenza virus hemagglutinin in the sample.

78. The nucleotide according to the claim 69, for a use of detecting nucleic acid encoding antigenic compound according to claim 1 in a sample comprising:

contacting the sample with a primer immobilized on a support, said primer comprising a sequence listed in Table 1 or sequences in FIGS. 17-19, under conditions suitable for hybridizing the primer and the sample; and

detecting hybridization of the primer and the sample or

for determining nucleic acid or amino acid sequence of the divalent sialoside binding site of a hemagglutinin protein of influenza virus comprising the steps of;

(a) isolating genomic nucleic acid of an influenza virus; and

(b) sequencing a nucleic acid sequence encoding the cysteine 97 region, cysteine 139 region and the region of amino acids 220-226 as defined by the amino acid sequence of X31-hemaglutinin,

wherein said method optionally comprises a further step of designing peptides for influenza vaccine development based on the sequencing results obtained in step (b) and optionally

the use further including contacting the sample with a nucleic acid microarray, the nucleic acid microarray comprising one or more primers, each of said primers comprising a sequence of any one listed in Table 1 or sequences in FIGS. 17-19, under conditions suitable for hybridizing the one or more primers and the sample;

and detecting hybridization of the one or more primers and the sample,

or optionally

the nucleotide being part of a nucleic acid microarray comprising a primer, said primer comprising a sequence of any one of Table 1 or sequences in FIGS. 17-19 or a kit comprising a primer and/or nucleic acid as defined above and instructions for detecting antigenic compound according to claim 1.

88. The method according to the claim 1, for identifying influenza virus in a biological sample, the method comprising:

(a) contacting the biological sample with an antibody substance capable of binding antigenic compound according to claim 1; and

(b) detecting the binding between said antibody substance and antigenic compound in the sample, said binding indicating the presence and type of influenza virus in the sample.

97. The substance according to claim 10, wherein the substance is according to Formula

[PEP-(y)_p-(S)_q-(z)_r-]_nPO 

 

(SP1)

wherein PO is an oligomeric or polymeric carrier structure, PEP is the peptide epitope sequence as defined for Peptide 1, Peptide 2 and Peptide 3, PO is preferably selected from the group consisting of;

a) solid phases, b) immunogenic and or oligomeric or polymeric carrier such as multiple antigen presenting (MAP) constructs, proteins such as KLH (keyhole limpet hemocyanin oligosaccharide or polysaccharide structure, n is an integer>

1 indicating the number of PEP groups covalently attached to the carrier PO, S is a spacer group, p, q and r are each 0 or 1, whereby at least one of p and r is different from 0, y and z are linking groups, at least one of y and z being a linking atom group also referred as “

chemoselective ligation group”

, in a preferred embodiment comprising at least one an O-hydroxylamine residue —

O—

NH—

or —

O—

N═

, with the nitrogen atom being linked to the OS and/or PO structure, respectively, and the other y and z, if present, is a chemoselective ligation group, with the proviso that when n is 1, the carrier structure is a monovalent immunogenic carrier.

2-5. -5. (canceled)

7. (canceled)

9. (canceled)

12-13. -13. (canceled)

15-20. -20. (canceled)

22-25. -25. (canceled)

27. (canceled)

29-32. -32. (canceled)

34-37. -37. (canceled)

39. (canceled)

41. (canceled)

44-56. -56. (canceled)

58-68. -68. (canceled)

71-77. -77. (canceled)

79-87. -87. (canceled)

89-96. -96. (canceled)